Molecular Epidemiology of Factor IX Germline Mutations in Mexican Hispanics: Pattern of Mutation and Potential Founder Effects

Summary

Germline mutations in patients with hemophilia B generally have arisen within the past 150 years. Evidence suggests that these germline mutations generally result from endogenous processes. However, a unique pattern would be expected if a population were exposed to a physiologically important germline mutagen since mutagens generally produce characteristic patterns, or “fingerprints”, of mutation. To determine the pattern of mutation in Mexican Hispanics, the regions of likely functional significance in the factor IX gene were screened by di-deoxy fingerprinting (ddF) in 31 families with hemophilia B. Mutations were found in 30 of these families. Haplotype analysis was performed on individuals with identical mutations to help distinguish independent, recurrent mutations from founder effects. Analysis of these 30 mutations, along with 7 mutations reported previously in Mexican Hispanic families, reveals a pattern of independent mutation that is similar to the pattern of mutation observed in 127 U. S. Caucasian families (p = 0.89). These results may reflect either an underlying pattern of germline mutation due to endogenous processes or the presence of an ubiquitous mutagen. Further analyses of the recurrent mutations revealed that two mutations, T296M and R248Q, accounted for 19% of the mutations found in the Mexicans. Haplotype data suggest that the multiple occurrences of T296M and R248Q are associated with founder effects and that screening for these mutations may allow rapid mutation detection and carrier diagnosis in a significant minority of Mexican families with hemophilia B. These two mutations also are associated with founder effects in the U. S. Caucasian population. However, the haplotypes are different in these two populations, indicating independent origins. The occurrence of identical founder mutations in distinct populations provides evidence for the previous hypothesis that the number of different mutations giving rise to mild or borderline mild/moderate hemophilia B is small compared to deleterious mutations causing more severe disease.

• References

• 1 Hedner U, Davie EW. In: The metabolic basis of inherited disease. Introduction to hemostasis and the vitamin K-dependent coagulation factor Scriver CR, Beaudet AL, Sly WS, Valle D. eds. New York: McGraw-Hill; 1989. pp 2107-2134
• 2 Haldane JB S. The rate of spontaneous mutation of a human gene. J Genet 1935; 31: 317-326
• 3 Sommer SS, Ketterling RP. How precisely can data from transgenic mouse mutation-detection systems be extrapolated to humans. Lessons from the human factor IX gene Mutat Res 1994; 307: 517-531
• 4 Yoshitake S, Schach BG, Foster DC, Davie EW, Kurachi K. Nucleotide sequence of the gene for human factor IX (anti-hemophilic factor B). Biochemistry 1985; 24: 3736-3750
• 5 Sommer SS. Assessing the underlying pattern of human germline mutations: lessons from the factor IX gene. FASEB J 1992; 6: 2767-2774
• 6 Sommer SS. Recent human germ-line mutation: inferences from patients with hemophilia B. Trends Genet 1995; 11: 141-147
• 7 Bottema CD K, Ketterling RP, Yoon H, Sommer SS. The pattern of factor IX germline mutation in Asians is similar to that of Caucasians. Am J Hum Genet 1990; 47: 835-841
• 8 Gostout B, Vielhaber E, Ketterling RP, Yoon H, Bottema CD K, Kasper CK, Koerper M, Sommer SS. Germline mutations in the factor IX gene: a comparison of the pattern in Caucasians and non-Caucasians. Hum Molec Genet 1993; 2: 293-298
• 9 Sommer SS. Mutagen test. Nature 1990; 346: 22-23
• 10 Bowie EJ W, Thompson JH Jr, Didisheim P, Owen Jr CA. In: Mayo Clinic Laboratory Manual of Hemostasis. Philadelphia: Anonymous Saunders; 1971
• 11 Gustafson S, Proper JA, Bowie EJ W, Sommer SS. Parameters affecting the yield of DNA from human blood. Anal Biochem 1987; 165: 294-299
• 12 Sarkar G, Yoon H, Sommer SS. Dideoxy fingerprinting (ddF): a rapid and efficient screen for the presence of mutations. Genomics 1992; 13: 441-443
• 13 Koeberl DD, Bottema CD K, Ketterling RP, Bridge PJ, Lillicrap DP, Sommer SS. Mutations causing hemophilia B: direct estimate of the underlying rates of spontaneous germ-line transitions, transversions, and deletions in the human gene. Am J Hum Genet 1990; 47: 202-217
• 14 Stoflet ES, Koeberl DD, Sarkar G, Sommer SS. Genomic amplification with transcript sequencing. Science 1988; 239: 491-494
• 15 Sommer SS, Sarkar G, Koeberl DD, Bottema CD K, Buerstedde J, Schowalter DB, Cassady JD. In: PCR Protocols: A Guide to Methods and Applications. Direct sequencing with the aid of phage promoters. Innis MA, Gelfand DH, Sninsky JJ, White TJ. eds. New York: Academic Press; 1990. pp 197-205
• 16 Winship PR, Nichols CE, Chuansumrit A, Peake IR. An Msel RFLP in the 5’flanking region of the factor IX gene: its use for hemophilia B carrier detection in Caucasian and Thai populations. Br J Haematol 1993; 84: 101-105
• 17 Zhang M, Chen S, Scott CR, Thompson AR. The factor IX BamHI polymorphism: T-to-G transversion at the nucleotide sequence-561. Hum Genet 1989; 82: 283-284
• 18 Winship PR, Anson DS, Rizza CR, Brownlee GG. Carrier detection in haemophilia B using two further intragenic restriction fragment length polymorphisms. Nucleic Acids Res 1984; 12: 8861-8872
• 19 Sarkar G, Paynton C, Sommer SS. Segments containing alternating purine and pyrimidine dinucleotides: patterns of polymorphism in humans and prevalence throughout phylogeny. Nucleic Acids Res 1991; 19: 631-636
• 20 Camerino G, Grzeschik KH, Jaye M, DeLaSalle H, Tolstoshev P, Lecocq JP, Heilig R, Mandel JL. Regional localization on the human X chromosome and polymorphism of the coagulation factor IX gene (hemophilia B locus). Proc Natl Acad Sci USA 1984; 81: 498-502
• 21 Sommer SS, Tillotson VL, Vielhaber EL, Ketterling RP, Dutton CM. ”Cryptic” dinucleotide polymorphism in the 3’region of the factor IX gene shows substantial variation among different populations. Hum Genet 1994; 93: 357-358
• 22 Winship PR, Rees DJ G, Alkan M. Detection of polymorphisms at cytosine phosphoguanadine dinucleotides and diagnosis of haemophilia B carriers. Lancet 1989; 1: 631-634
• 23 Bottema CD K, Ketterling RP, Vielhaber E, Yoon H, Gostout B, Jacobson DP, Shapiro A, Sommer SS. The pattern of spontaneous germline mutation: relative rates of mutation at or near CpG dinucleotides in the factor IX gene. Hum Genet 1993; 91: 496-503
• 24 Ketterling RP, Bottema CD K, Phillips III JP, Sommer SS. Evidence that descendants of three founders comprise about 25% of hemophilia B in the United States. Genomics 1991; 10: 1093-1096
• 25 Eyster ME, Lewis JH, Shapiro SS, Gill F, Kajani M, Prager D, Djerassi I, Rice S, Lusch C, Keller A. The Pennsylvania hemophilia program 1973-1978. Am J Hematol 1980; 9: 277-286
• 26 Mehta CR, Patel NR. A network algorithm for performing Fisher’s exact test in r x c contingency tables. J Am Stat Assoc 1983; 78: 427-434
• 27 Bottema CD K, Ketterling RP, Ii S, Yoon H, Phillips III JA, Sommer SS. Missense mutations and evolutionary conservation of amino acids: evidence that many of the amino acids in factor IX function as “spacer” elements. Am J Hum Genet 1991; 49: 820-838
• 28 Ketterling RP, Liu J, Liao D, Kasper CK, Ambriz R, Paredes R, Sommer SS. Two novel factor IX promoter mutations: incremental progress towards “saturation in vivo mutagenesis” of a human promoter region. Hum Mol Genet 1995; 4: 769-770
• 29 Giannelli F, Green PM, Sommer SS, Lillicrap DP, Ludwig M, Schwaab R, Reitsma PH, Goossens M, Yoshioka A, Brownlee GG. Haemophilia B: database of point mutations and short additions and deletions, fifth edition. 1994; Nucleic Acids Res 1994; 22: 3534-3546
• 30 Ketterling RP, Vielhaber E, Sommer SS. The rates of G:C → T:A and G:C → C:G transversions at CpG dinucleotides in the human factor IX gene. Am J Hum Genet 1994; 54: 831-835
• 31 Ludwig M, Sabharwal AK, Brackman HH, Olek K, Smith KJ, Birktoft JJ, Bajaj SP. Hemophilia B caused by five different nondeletion mutations in the protease domain of factor IX. Blood 1992; 79: 1225-1232
• 32 Suzuki DT, Griffiths AJ F, Miller JH, Lewontin RC. In: An introduction to genetic analysis. 4th ed. Suzuki DT, Griffiths AJ F, Miller JH, Lewontin RC. eds. New York: W. H. Freeman and Company; 1989
• 33 Chiba I, Takahashi T, Nau NM, D’Amico D, Curiel DT, Mitsudomi T, Buchhagen DL, Carbone D, Piantadosi S, Koga H, Reissman PT, Slamon DJ, Holmes EC, Minna JD. Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Oncogene 1990; 5: 1603-1610
• 34 Bressac B, Kew M, Wands J, Ozturk M. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature 1991; 350: 429-431
• 35 Hsu IC, Metcalf RA, Sun T, Welsh JA, Wang NJ, Harris CC. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature 1991; 350: 427-428
• 36 Brash DE, Rudolph JA, Simon JA, Lin A, McKenna GJ, Baden HP, Halperin AJ, Ponten J. A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. Proc Natl Acad Sci USA 1991; 88: 10124-10128
• 37 Green PM, Montandon AJ, Ljung R, Bentley DR, Nilsson IM, Kling S, Giannelli F. Haemophilia B mutations in a complete Swedish population sample: a test of new strategy for the genetic counselling of diseases with high mutational heterogeneity. Br J Haematol 1991; 78: 390-397
• 38 Bottema CD K, Bottema MJ, Ketterling RP, Yoon H, Janco RL, Phillips III JA, Sommer SS. Why does the human factor IX gene have a G + C content of 40%. Am J Hum Genet 1991; 49: 839-850
• 39 Coulondre C, Miller JH, Farabaugh PJ, Gilbert W. Molecular basis of base substitution hotspots in E. coli. Nature 1978; 274: 775-780
• 40 Scriver CR, Beaudet AL, Sly WS, Valle D. In: The metabolic and molecular bases of inherited diseases. 7th ed. Jeffersen JD, Gavert G, Englis MR, McCurdy P. eds. New York: McGraw-Hill, Inc; 1995
• 41 Bottema CD K, Koeberl DD, Ketterling RP, Bowie EJ W, Taylor SA M, Bridge PJ, Lillicrap D, Shapiro A, Gilchrist G, Sommer SS. A past mutation at isoleucine³⁹⁷is now a common cause of moderate/mild haemophilia B. Br J Haematol 1990; 75: 212-216
• 42 Thompson AR, Bajaj SP, Chen S, MacGillivray RT A. “Founder” effect in different families with haemophilia B mutation. Lancet 1990; 1: 418
• 43 Ketterling RP, Bottema CD K, Koeberl DD, Ii S, Sommer SS. T²⁹⁶→ M, a common mutation causing mild hemophilia B in the Amish and others: founder effect, variability in factor IX activity assays, and rapid carrier detection. Hum Genet 1991; 87: 333-337
• 44 Sommer SS, Bowie EJ W, Ketterling RP, Bottema CD K. Missense mutations and the magnitude of functional deficit: the example of factor IX. Hum Genet 1992; 89: 295-297
• 45 Knobloch O, Zoll B, Zerres K, Brackmann H-H, Olek K, Ludwig M. Recurrent mutations in the factor IX gene: founder effect or repeat de novo events. Hum Genet 1993; 92: 40-48
• 46 Jacobson DP, Schmeling P, Sommer SS. Characterization of the patterns of polymorphism in a “cryptic repeat” reveals a novel type of hypervariable sequence. Am J Hum Genet 1993; 53: 443-450